"Metformin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
| Descriptor ID |
D008687
|
| MeSH Number(s) |
D02.078.370.141.450
|
| Concept/Terms |
Metformin- Metformin
- Dimethylbiguanidine
- Dimethylguanylguanidine
|
Below are MeSH descriptors whose meaning is more general than "Metformin".
Below are MeSH descriptors whose meaning is more specific than "Metformin".
This graph shows the total number of publications written about "Metformin" by people in this website by year, and whether "Metformin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 0 | 3 | 3 |
| 2008 | 1 | 0 | 1 |
| 2010 | 2 | 1 | 3 |
| 2013 | 0 | 5 | 5 |
| 2014 | 1 | 0 | 1 |
| 2015 | 6 | 1 | 7 |
| 2016 | 2 | 0 | 2 |
| 2017 | 2 | 2 | 4 |
| 2018 | 2 | 0 | 2 |
| 2019 | 3 | 0 | 3 |
| 2020 | 2 | 1 | 3 |
| 2021 | 1 | 0 | 1 |
| 2022 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Metformin" by people in Profiles.
-
Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes. N Engl J Med. 2022 09 22; 387(12):1075-1088.
-
Screening for Prediabetes and Type 2 Diabetes in Children and Adolescents: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2022 09 13; 328(10):968-979.
-
Weight loss and ß-cell responses following gastric banding or pharmacotherapy in adults with impaired glucose tolerance or type 2 diabetes: a randomized trial. Obesity (Silver Spring). 2022 08; 30(8):1579-1588.
-
Diabetes and pancreatic cancer: recent insights with implications for early diagnosis, treatment and prevention. Curr Opin Gastroenterol. 2021 09 01; 37(5):539-543.
-
Risk of incident dementia following metformin initiation compared with noninitiation or delay of antidiabetic medication therapy. Pharmacoepidemiol Drug Saf. 2020 06; 29(6):623-634.
-
Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight. Diabetes Care. 2020 05; 43(5):940-947.
-
Initial Glycemic Control and Care Among Younger Adults Diagnosed With Type 2 Diabetes. Diabetes Care. 2020 05; 43(5):975-981.
-
Metformin and Sulfonylurea Use and Risk of Incident Dementia. Mayo Clin Proc. 2019 08; 94(8):1444-1456.
-
Association Between Metformin Initiation and Incident Dementia Among African American and White Veterans Health Administration Patients. Ann Fam Med. 2019 07; 17(4):352-362.
-
A benefit-harm analysis of adding basal insulin vs. sulfonylurea to metformin to manage type II diabetes mellitus in people with multiple chronic conditions. J Clin Epidemiol. 2019 09; 113:92-100.